News & Updates

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

06/03/2025

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS…

Read More

Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies

06/03/2025

Novel approach targeting KAT2A/B with preclinical validation across multiple cancer models and tumor types Excerpt from the Press Release: NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been dosed with…

Read More

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

06/02/2025

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program Excerpt from the Press Release: WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or…

Read More

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

05/30/2025

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for…

Read More

Join The TrialStat Team in Chicago at ASCO!

05/29/2025

The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at ASCO 2025. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing Oncology research and streamlining clinical trial execution for Sponsors and CROs. Meet with Christopher and Nick at this exciting event and you’ll…

Read More

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

05/29/2025

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor Excerpt from the Press Release: SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology…

Read More

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

05/28/2025

Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are not candidates for transplant – – 89% of patients whose cancer had fully responded at the end of treatment with Columvi in combination with…

Read More

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

05/27/2025

Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–May 22, 2025– Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase…

Read More

World’s First Patient Treated with Personalized CRISPR Gene Editing Therapy at Children’s Hospital of Philadelphia

05/23/2025

Landmark Study from CHOP and Penn Medicine Showcases the Power of Customized Gene Editing Therapy to Treat Patient with Rare Metabolic Disease Excerpt from the Press Release: PHILADELPHIA and NEW ORLEANS, May 15, 2025 /PRNewswire/ — In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR…

Read More

Orna Therapeutics Presents New Preclinical Data Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases at the American Society of Gene and Cell Therapy Annual Meeting

05/22/2025

Excerpt from the Press Release: WATERTOWN, Mass., May 15, 2025 /PRNewswire/ — Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during an…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives